138th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2170401296151939 Karnataka164924842322998 Delhi1441271293624098 Uttar Pradesh118038698332028 West Bengal89666630601954 Telangana7751354330615 Bihar7578648673419 Gujarat68855517922604 Assam5549737225132 Rajasthan5065636310776 Odisha4419328698307 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3312020862107 Jammu and Kashmir2439020862459 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Tripura6014408437 Puducherry5123291475 Manipur3635192711 Himachal Pradesh3242201513 Nagaland26888937 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
Business Companies 09 Jul 2020 Gilead starts testin ...

Gilead starts testing inhaled version of remdesivir for COVID-19

REUTERS
Published Jul 9, 2020, 9:07 am IST
Updated Jul 9, 2020, 9:11 am IST
Gilead also plans to start additional clinical trials to evaluate remdesivir when used in combination with anti-inflammatory medicines
Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled. (AFP Photo)
 Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled. (AFP Photo)

Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.

The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalization.

 

The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals.

Remdesivir was granted emergency use authorization in the United States to treat severe cases of COVID-19 in patients who are hospitalized.

Gilead is hoping to target the disease at the onset with the inhaled form of remdesivir, by delivering the drug directly to the primary site of infection.

Remdesivir is believed to be at the forefront in the fight against the coronavirus after the drug helped shorten hospital recovery times in a clinical trial.

 

Gilead also plans to start additional clinical trials to evaluate remdesivir when used in combination with anti-inflammatory medicines.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT